Emad A Rakha

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4793805/publications.pdf

Version: 2024-02-01

428 papers	28,096 citations	11608 70 h-index	7931 149 g-index
445 all docs	445 docs citations	445 times ranked	32111 citing authors

#	Article	IF	Citations
1	The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature, 2012, 486, 346-352.	13.7	4,708
2	Prognostic markers in triple-negative breast cancer. Cancer, 2007, 109, 25-32.	2.0	1,091
3	Basal-Like Breast Cancer: A Critical Review. Journal of Clinical Oncology, 2008, 26, 2568-2581.	0.8	784
4	Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies. PLoS Medicine, 2010, 7, e1000279.	3.9	764
5	A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Modern Pathology, 2018, 31, 1770-1786.	2.9	739
6	Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Research, 2010, 12, 207.	2.2	650
7	Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients. Annals of Oncology, 2014, 25, 1536-1543.	0.6	610
8	Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Modern Pathology, 2011, 24, 157-167.	2.9	545
9	High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. International Journal of Cancer, 2005, 116, 340-350.	2.3	500
10	Prognostic Significance of Nottingham Histologic Grade in Invasive Breast Carcinoma. Journal of Clinical Oncology, 2008, 26, 3153-3158.	0.8	462
11	Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes. Clinical Cancer Research, 2009, 15, 2302-2310.	3.2	422
12	Global Histone Modifications in Breast Cancer Correlate with Tumor Phenotypes, Prognostic Factors, and Patient Outcome. Cancer Research, 2009, 69, 3802-3809.	0.4	417
13	Phyllodes tumours of the breast: a consensus review. Histopathology, 2016, 68, 5-21.	1.6	329
14	Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Research, 2013, 15, R92.	2.2	320
15	Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Modern Pathology, 2005, 18, 1295-1304.	2.9	305
16	Biologic and Clinical Characteristics of Breast Cancer With Single Hormone Receptorâ€“Positive Phenotype. Journal of Clinical Oncology, 2007, 25, 4772-4778.	0.8	261
17	Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Modern Pathology, 2005, 18, 26-35.	2.9	232
18	Triple-negative/basal-like breast cancer: review. Pathology, 2009, 41, 40-47.	0.3	226

#	Article	IF	Citations
19	Invasive lobular carcinoma of the breast: Response to hormonal therapy and outcomes. European Journal of Cancer, 2008, 44, 73-83.	1.3	206
20	Updated UK Recommendations for HER2 assessment in breast cancer. Journal of Clinical Pathology, 2015, 68, 93-99.	1.0	203
21	The prognostic significance of lymphovascular invasion in invasive breast carcinoma. Cancer, 2012, 118, 3670-3680.	2.0	197
22	Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen. Breast Cancer Research and Treatment, 2010, 119, 283-293.	1.1	193
23	Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. European Journal of Cancer, 2006, 42, 3149-3156.	1.3	179
24	Combinatorial biomarker expression in breast cancer. Breast Cancer Research and Treatment, 2010, 120, 293-308.	1.1	176
25	PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. British Journal of Cancer, 2012, 107, 800-807.	2.9	163
26	An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation. Breast Cancer Research, 2017, 19, 58.	2.2	161
27	Tubular Carcinoma of the Breast: Further Evidence to Support Its Excellent Prognosis. Journal of Clinical Oncology, 2010, 28, 99-104.	0.8	154
28	Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression. Histopathology, 2007, 50, 434-438.	1.6	152
29	E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance. Histopathology, 2005, 46, 685-693.	1.6	150
30	IL6/STAT3 Signaling Hijacks Estrogen Receptor Î± Enhancers to Drive Breast Cancer Metastasis. Cancer Cell, 2020, 38, 412-423.e9.	7.7	145
31	Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype. British Journal of Cancer, 2008, 99, 327-334.	2.9	139
32	Lobular Neoplasia of the Breast Revisited With Emphasis on the Role of E-Cadherin Immunohistochemistry. American Journal of Surgical Pathology, 2013, 37, e1-e11.	2.1	137
33	Expression of BRCA1 protein in breast cancer and its prognostic significance. Human Pathology, 2008, 39, 857-865.	1.1	133
34	Clinical and Biological Significance of E-cadherin Protein Expression in Invasive Lobular Carcinoma of the Breast. American Journal of Surgical Pathology, 2010, 34, 1472-1479.	2.1	132
35	Predictive value of needle core biopsy diagnoses of lesions of uncertain malignant potential (B3) in abnormalities detected by mammographic screening. Histopathology, 2008, 53, 650-657.	1.6	131
36	Caspase-3 and caspase-8 expression in breast cancer: caspase-3 is associated with survival. Apoptosis: an International Journal on Programmed Cell Death, 2017, 22, 357-368.	2.2	124

#	Article	IF	Citations
37	Histologic grading is an independent prognostic factor in invasive lobular carcinoma of the breast. Breast Cancer Research and Treatment, 2008, 111, 121-127.	1.1	122
38	Lobular breast carcinoma and its variants. Seminars in Diagnostic Pathology, 2010, 27, 49-61.	1.0	122
39	Encapsulated Papillary Carcinoma of the Breast. American Journal of Surgical Pathology, 2011, 35, 1093-1103.	2.1	122
40	The Spectrum of Triple-Negative Breast Disease. American Journal of Pathology, 2017, 187, 2139-2151.	1.9	118
41	Artificial intelligence in digital breast pathology: Techniques and applications. Breast, 2020, 49, 267-273.	0.9	117
42	Lymphatic and blood vessels in basal and triple-negative breast cancers: characteristics and prognostic significance. Modern Pathology, 2011, 24, 774-785.	2.9	114
43	A Case-Controlled Study of the Oncologic Safety of Fat Grafting. Plastic and Reconstructive Surgery, 2015, 135, 1263-1275.	0.7	108
44	Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer. Breast Cancer Research, 2012, 14, R3.	2.2	105
45	Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas. Nature Communications, 2018, 9, 1816.	5.8	105
46	The role of glutaminase in cancer. Histopathology, 2020, 76, 498-508.	1.6	101
47	Are triple-negative tumours and basal-like breast cancer synonymous?. Breast Cancer Research, 2007, 9, 404; author reply 405.	2.2	98
48	Metastatic Triple-negative Breast Cancer. Clinical Oncology, 2011, 23, 587-600.	0.6	95
49	MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups. Breast Cancer Research and Treatment, 2011, 127, 591-599.	1.1	93
50	Prognostic factors in metaplastic carcinoma of the breast: a multi-institutional study. British Journal of Cancer, 2015, 112, 283-289.	2.9	93
51	Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors. Nature Communications, 2018, 9, 3533.	5.8	92
52	Characterization and outcome of breast needle core biopsy diagnoses of lesions of uncertain malignant potential (B3) in abnormalities detected by mammographic screening. International Journal of Cancer, 2011, 129, 1417-1424.	2.3	91
53	MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours. British Journal of Cancer, 2016, 114, 917-928.	2.9	91
54	A CD44â^'/CD24+ phenotype is a poor prognostic marker in early invasive breast cancer. Breast Cancer Research and Treatment, 2012, 133, 979-995.	1.1	89

#	Article	IF	Citations
55	Targeting XRCC1 Deficiency in Breast Cancer for Personalized Therapy. Cancer Research, 2013, 73, 1621-1634.	0.4	88
56	Breast tumor microenvironment structures are associated with genomic features and clinical outcome. Nature Genetics, 2022, 54, 660-669.	9.4	88
57	The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours. Breast Cancer Research, 2018, 20, 21.	2.2	85
58	Nottingham Prognostic Index Plus (NPI+): a modern clinical decision making tool in breast cancer. British Journal of Cancer, 2014, 110, 1688-1697.	2.9	84
59	The prognostic significance of PELP1 expression in invasive breast cancer with emphasis on the ER-positive luminal-like subtype. Breast Cancer Research and Treatment, 2010, 120, 603-612.	1.1	83
60	Molecular classification of breast cancer: what the pathologist needs to know. Pathology, 2017, 49, 111-119.	0.3	83
61	Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis. Breast Cancer Research and Treatment, 2016, 159, 215-227.	1.1	81
62	Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance. European Journal of Cancer, 2008, 44, 1541-1551.	1.3	79
63	Loss of Dicer expression is associated with breast cancer progression and recurrence. Breast Cancer Research and Treatment, 2012, 135, 403-413.	1.1	77
64	Towards intra-operative diagnosis of tumours during breast conserving surgery by selective-sampling Raman micro-spectroscopy. Physics in Medicine and Biology, 2014, 59, 6141-6152.	1.6	77
65	Intra-operative spectroscopic assessment of surgical margins during breast conserving surgery. Breast Cancer Research, 2018, 20, 69.	2.2	77
66	Tumor size is an unreliable predictor of prognosis in basal-like breast cancers and does not correlate closely with lymph node status. Breast Cancer Research and Treatment, 2009, 117, 199-204.	1.1	76
67	Immune Infiltration in Invasive Lobular Breast Cancer. Journal of the National Cancer Institute, 2018, 110, 768-776.	3.0	76
68	Chromosome 16 tumor-suppressor genes in breast cancer. Genes Chromosomes and Cancer, 2006, 45, 527-535.	1.5	75
69	Untangling the ATRâ€CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer. Molecular Oncology, 2015, 9, 569-585.	2.1	75
70	MYC regulation of glutamineâ€“proline regulatory axis is key in luminal B breast cancer. British Journal of Cancer, 2018, 118, 258-265.	2.9	74
71	PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis. Breast Cancer Research and Treatment, 2010, 122, 45-53.	1.1	73
72	Patho-biological aspects of basal-like breast cancer. Breast Cancer Research and Treatment, 2009, 113, 411-422.	1.1	72

#	Article	IF	Citations
73	Targeting BRCA1â€BER deficient breast cancer by ATM or DNAâ€PKcs blockade either alone or in combination with cisplatin for personalized therapy. Molecular Oncology, 2015, 9, 204-217.	2.1	72
74	The sensitivity of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Diagnostic Cytopathology, 2010, 38, 874-879.	0.5	69
75	FOXO3a nuclear localisation is associated with good prognosis in luminal-like breast cancer. Breast Cancer Research and Treatment, 2011, 129, 11-21.	1.1	69
76	Clinical Outcome of Atypical Endometrial Hyperplasia Diagnosed on an Endometrial Biopsy. American Journal of Surgical Pathology, 2012, 36, 1683-1690.	2.1	69
77	The updated <scp>ASCO</scp>/<scp>CAP</scp> guideline recommendations for <scp>HER</scp>2 testing in the management of invasive breast cancer: a critical review of their implications for routine practice. Histopathology, 2014, 64, 609-615.	1.6	68
78	Clinical and biological significance of glucocorticoid receptor (GR) expression in breast cancer. Breast Cancer Research and Treatment, 2015, 150, 335-346.	1.1	68
79	IL-6 and IL-10 are associated with good prognosis in early stage invasive breast cancer patients. Cancer Immunology, Immunotherapy, 2018, 67, 537-549.	2.0	67
80	Biological and clinical significance of PARP1 protein expression in breast cancer. Breast Cancer Research and Treatment, 2015, 149, 353-362.	1.1	66
81	Expression of CDK7, Cyclin H, and MAT1 Is Elevated in Breast Cancer and Is Prognostic in Estrogen Receptorâ€“Positive Breast Cancer. Clinical Cancer Research, 2016, 22, 5929-5938.	3.2	66
82	Basal-like Breast Carcinoma: From Expression Profiling to Routine Practice. Archives of Pathology and Laboratory Medicine, 2009, 133, 860-868.	1.2	66
83	Tumour Heterogeneity of Breast Cancer: From Morphology to Personalised Medicine. Pathobiology, 2018, 85, 23-34.	1.9	65
84	Modern Classification of Breast Cancer. Advances in Anatomic Pathology, 2011, 18, 255-267.	2.4	64
85	A validated gene expression profile for detecting clinical outcome in breast cancer using artificial neural networks. Breast Cancer Research and Treatment, 2010, 120, 83-93.	1.1	62
86	Heterogeneity of tumourâ€infiltrating lymphocytes in breast cancer and its prognostic significance. Histopathology, 2018, 73, 887-896.	1.6	62
87	Increased expression of glutamine transporter SNAT2/SLC38A2 promotes glutamine dependence and oxidative stress resistance, and is associated with worse prognosis in triple-negative breast cancer. British Journal of Cancer, 2021, 124, 494-505.	2.9	62
88	Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents. Breast Cancer Research, 2015, 17, 59.	2.2	61
89	Altered glutamine metabolism in breast cancer; subtype dependencies and alternative adaptations. Histopathology, 2018, 72, 183-190.	1.6	60
90	Molecular Mechanisms Underlying Lymphovascular Invasion in Invasive Breast Cancer. Pathobiology, 2015, 82, 113-123.	1.9	59

#	Article	IF	Citations
91	Outcome of breast lesions diagnosed as lesion of uncertain malignant potential (B3) or suspicious of malignancy (B4) on needle core biopsy, including detailed review of epithelial atypia. Histopathology, 2011, 58, 626-632.	1.6	58
92	Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma in situ. Histopathology, 2017, 71, 258-268.	1.6	58
93	Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival. Breast Cancer Research and Treatment, 2020, 182, 267-282.	1.1	58
94	The prognostic significance of steroid receptor co-regulators in breast cancer: co-repressor NCOR2/SMRT is an independent indicator of poor outcome. Breast Cancer Research and Treatment, 2008, 110, 427-437.	1.1	57
95	Immunoprofile of metaplastic carcinomas of the breast. Histopathology, 2017, 70, 975-985.	1.6	57
96	Current and future applications of artificial intelligence in pathology: a clinical perspective. Journal of Clinical Pathology, 2021, 74, 409-414.	1.0	57
97	Clinicopathological significance of KU70/KU80, a key DNA damage repair protein in breast cancer. Breast Cancer Research and Treatment, 2013, 139, 301-310.	1.1	56
98	Clinical Impact of Tumor DNA Repair Expression and T-cell Infiltration in Breast Cancers. Cancer Immunology Research, 2017, 5, 292-299.	1.6	56
99	Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast. Modern Pathology, 2018, 31, 1226-1236.	2.9	56
100	A methodology to identify consensus classes from clustering algorithms applied to immunohistochemical data from breast cancer patients. Computers in Biology and Medicine, 2010, 40, 318-330.	3.9	55
101	Epithelial mesenchymal transition in early invasive breast cancer: an immunohistochemical and reverse phase protein array study. Breast Cancer Research and Treatment, 2014, 145, 339-348.	1.1	55
102	KPNA2 is a nuclear export protein that contributes to aberrant localisation of key proteins and poor prognosis of breast cancer. British Journal of Cancer, 2015, 112, 1929-1937.	2.9	55
103	Metadherin: A Therapeutic Target in Multiple Cancers. Frontiers in Oncology, 2019, 9, 349.	1.3	55
104	The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesisâ€generating study. Journal of Pathology, 2015, 237, 166-178.	2.1	53
105	Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer. Breast Cancer Research and Treatment, 2019, 174, 387-399.	1.1	53
106	Determining breast cancer biomarker status and associated morphological features using deep learning. Communications Medicine, 2021, 1, .	1.9	53
107	Loss of expression of chromosome 16q genes DPEP1 and CTCF in lobular carcinoma in situ of the breast. Breast Cancer Research and Treatment, 2009, 113, 59-66.	1.1	52
108	Sonographic correlations with the new molecular classification of invasive breast cancer. European Radiology, 2009, 19, 2342-2348.	2.3	52

#	Article	IF	Citations
109	Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer. Breast Cancer Research and Treatment, 2011, 127, 407-416.	1.1	52
110	Do primary mammary osteosarcoma and chondrosarcoma exist? A review of a large multi-institutional series of malignant matrix-producing breast tumours. Breast, 2013, 22, 13-18.	0.9	52
111	Microglandular adenosis associated with tripleâ€negative breast cancer is a neoplastic lesion of tripleâ€negative phenotype harbouring <scp>TP53</scp> somatic mutations. Journal of Pathology, 2016, 238, 677-688.	2.1	52
112	Histological features of medullary carcinoma and prognosis in triple-negative basal-like carcinomas of the breast. Modern Pathology, 2010, 23, 1357-1363.	2.9	51
113	Portal inflammation is associated with advanced histological changes in alcoholic and non-alcoholic fatty liver disease. Journal of Clinical Pathology, 2010, 63, 790-795.	1.0	51
114	Highâ€grade encapsulated papillary carcinoma of the breast: an underâ€recognized entity. Histopathology, 2015, 66, 740-746.	1.6	51
115	Involvement of metformin and AMPK in the radioresponse and prognosis of luminal versus basal-like breast cancer treated with radiotherapy. Oncotarget, 2014, 5, 12936-12949.	0.8	51
116	An approach to the diagnosis of spindle cell lesions of the breast. Histopathology, 2016, 68, 33-44.	1.6	50
117	Breast cancer intratumour heterogeneity: current status and clinical implications. Histopathology, 2018, 73, 717-731.	1.6	50
118	Digital pathology and artificial intelligence will be key to supporting clinical and academic cellular pathology through COVID-19 and future crises: the PathLAKE consortium perspective. Journal of Clinical Pathology, 2021, 74, 443-447.	1.0	49
119	Genetic analysis of microglandular adenosis and acinic cell carcinomas of the breast provides evidence for the existence of a low-grade triple-negative breast neoplasia family. Modern Pathology, 2017, 30, 69-84.	2.9	48
120	The biological and clinical characteristics of breast carcinoma with mixed ductal and lobular morphology. Breast Cancer Research and Treatment, 2009, 114, 243-250.	1.1	47
121	The proteins FABP7 and OATP2 are associated with the basal phenotype and patient outcome in human breast cancer. Breast Cancer Research and Treatment, 2010, 121, 41-51.	1.1	47
122	Molecular characteristics and prognostic features of breast cancer in Nigerian compared with UK women. Breast Cancer Research and Treatment, 2012, 135, 555-569.	1.1	47
123	Outcome of pure mucoceleâ€like lesions diagnosed on breast core biopsy. Histopathology, 2013, 62, 894-898.	1.6	47
124	DNA damage repair in breast cancer and its therapeutic implications. Pathology, 2017, 49, 156-165.	0.3	47
125	Are Triple-Negative and Basal-Like Breast Cancer Synonymous?. Clinical Cancer Research, 2008, 14, 618-618.	3.2	45
126	The pioneer factor PBX1 is a novel driver of metastatic progression in ERÎ±-positive breast cancer. Oncotarget, 2015, 6, 21878-21891.	0.8	45

#	Article	IF	Citations
127	Histological grading of breast cancer on needle core biopsy: the role of immunohistochemical assessment of proliferation. Histopathology, 2010, 57, 212-219.	1.6	44
128	Lymph-node metastases in invasive lobular carcinoma are different from those in ductal carcinoma of the breast. Journal of Clinical Pathology, 2011, 64, 995-1000.	1.0	44
129	Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections. Breast Cancer Research and Treatment, 2017, 164, 341-348.	1.1	44
130	Solid papillary breast carcinomas resembling the tall cell variant of papillary thyroid neoplasms (solid papillary carcinomas with reverse polarity) harbour recurrent mutations affecting <scp>IDH</scp>2 and <scp>PIK</scp>3<scp>CA</scp>: a validation cohort. Histopathology, 2018, 73, 339-344.	1.6	44
131	Metaplastic breast carcinoma: tumour histogenesis or dedifferentiation?. Journal of Pathology, 2011, 224, 434-437.	2.1	43
132	Câ€Met in invasive breast cancer. Cancer, 2014, 120, 163-171.	2.0	43
133	<scp>RECQL4</scp> helicase has oncogenic potential in sporadic breast cancers. Journal of Pathology, 2016, 238, 495-501.	2.1	43
134	The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes. British Journal of Cancer, 2018, 118, 1115-1122.	2.9	43
135	Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer. Modern Pathology, 2021, 34, 1271-1281.	2.9	43
136	Expression profiling technology: its contribution to our understanding of breast cancer. Histopathology, 2008, 52, 67-81.	1.6	42
137	Investigating AP-2 and YY1 protein expression as a cause of high HER2 gene transcription in breast cancers with discordant HER2 gene amplification. Breast Cancer Research, 2009, 11, R90.	2.2	42
138	Inclusion of KI67 significantly improves performance of the PREDICT prognostication and prediction model for early breast cancer. BMC Cancer, 2014, 14, 908.	1.1	42
139	Transcriptomic and Protein Expression Analysis Reveals Clinicopathological Significance of Bloom Syndrome Helicase (BLM) in Breast Cancer. Molecular Cancer Therapeutics, 2015, 14, 1057-1065.	1.9	42
140	Vacuum-assisted excision of breast lesions of uncertain malignant potential (B3) â€“ an alternative to surgery in selected cases. Breast, 2008, 17, 546-549.	0.9	41
141	Breast Carcinoma with Basal Phenotype: Mammographic Findings. American Journal of Roentgenology, 2008, 191, 346-351.	1.0	41
142	RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype. Breast Cancer Research and Treatment, 2011, 128, 315-326.	1.1	41
143	Encapsulated papillary carcinoma of the breast: a study of invasion associated markers. Journal of Clinical Pathology, 2012, 65, 710-714.	1.0	41
144	Pleomorphic lobular carcinoma of the breast: is it a prognostically significant pathological subtype independent of histological grade?. Modern Pathology, 2013, 26, 496-501.	2.9	41

#	Article	IF	Citations
145	The molecular mechanisms underlying reduced E-cadherin expression in invasive ductal carcinoma of the breast: high throughput analysis of large cohorts. Modern Pathology, 2019, 32, 967-976.	2.9	41
146	The prognostic value of the tumorâ€“stroma ratio is most discriminative in patients with grade III or tripleâ€negative breast cancer. International Journal of Cancer, 2020, 146, 2296-2304.	2.3	41
147	Triple-Negative Breast Cancer Histological Subtypes with a Favourable Prognosis. Cancers, 2021, 13, 5694.	1.7	41
148	The p53 positive Bcl-2 negative phenotype is an independent marker of prognosis in breast cancer. International Journal of Cancer, 2007, 120, 1311-1317.	2.3	40
149	Identification of key clinical phenotypes of breast cancer using a reduced panel of protein biomarkers. British Journal of Cancer, 2013, 109, 1886-1894.	2.9	40
150	The oestrogen receptor coactivator CARM1 has an oncogenic effect and is associated with poor prognosis in breast cancer. Breast Cancer Research and Treatment, 2013, 140, 307-316.	1.1	40
151	DNA damage response markers are differentially expressed in BRCA-mutated breast cancers. Breast Cancer Research and Treatment, 2015, 150, 81-90.	1.1	40
152	Diagnostic challenges in papillary lesions of the breast. Pathology, 2018, 50, 100-110.	0.3	40
153	A whole slide image-based machine learning approach to predict ductal carcinoma in situ (DCIS) recurrence risk. Breast Cancer Research, 2019, 21, 83.	2.2	39
154	SlideGraph<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" altimg="si3.svg"><mml:msup><mml:mrow /><mml:mo>+</mml:mo></mml:msup></mml:math>: Whole slide image level graphs to predict HER2 status in breast cancer. Medical Image Analysis, 2022, 80, 102486.	7.0	39
155	Audit of performance of needle core biopsy diagnoses of screen detected breast lesions. European Journal of Cancer, 2008, 44, 2580-2586.	1.3	38
156	A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer. Molecular Oncology, 2015, 9, 115-127.	2.1	38
157	Atypical ductal hyperplasia: update on diagnosis, management, and molecular landscape. Breast Cancer Research, 2018, 20, 39.	2.2	38
158	Expression of E2F-4 in invasive breast carcinomas is associated with poor prognosis. Journal of Pathology, 2004, 203, 754-761.	2.1	37
159	Clinicopathological Significance of ATM-Chk2 Expression in Sporadic Breast Cancers: a Comprehensive Analysis in Large Cohorts. Neoplasia, 2014, 16, 982-991.	2.3	37
160	Are acinic cell carcinomas of the breast and salivary glands distinct diseases?. Histopathology, 2015, 67, 529-537.	1.6	37
161	Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein. Breast Cancer Research and Treatment, 2016, 159, 41-53.	1.1	37
162	Breast lesions of uncertain malignant nature and limited metastatic potential: proposals to improve their recognition and clinical management. Histopathology, 2016, 68, 45-56.	1.6	37

#	Article	IF	Citations
163	New Advances in Molecular Breast Cancer Pathology. Seminars in Cancer Biology, 2021, 72, 102-113.	4.3	37
164	Growth fraction as a predictor of response to chemotherapy in nodeâ€negative breast cancer. International Journal of Cancer, 2010, 126, 1761-1769.	2.3	36
165	Nottingham Prognostic Index Plus: Validation of a clinical decision making tool in breast cancer in an independent series. Journal of Pathology: Clinical Research, 2016, 2, 32-40.	1.3	36
166	Review of the national external quality assessment (EQA) scheme for breast pathology in the UK. Journal of Clinical Pathology, 2017, 70, 51-57.	1.0	36
167	CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy. Breast Cancer Research and Treatment, 2019, 178, 535-544.	1.1	36
168	Inflammatory breast cancer: time to standardise diagnosis assessment and management, and for the joining of forces to facilitate effective research. British Journal of Cancer, 2015, 112, 1613-1615.	2.9	35
169	Checkpoint kinase1 (CHK1) is an important biomarker in breast cancer having a role in chemotherapy response. British Journal of Cancer, 2015, 112, 901-911.	2.9	35
170	National Guidelines and Level of Evidence: Comments on Some of the New Recommendations in the American Society of Clinical Oncology and the College of American Pathologists Human Epidermal Growth Factor Receptor 2 Guidelines for Breast Cancer. Journal of Clinical Oncology, 2015, 33, 1301-1302.	0.8	35
171	Loss of the Nuclear Pool of Ubiquitin Ligase CHIP/STUB1 in Breast Cancer Unleashes the MZF1-Cathepsin Pro-oncogenic Program. Cancer Research, 2018, 78, 2524-2535.	0.4	35
172	Breast cancer histologic grading using digital microscopy: concordance and outcome association. Journal of Clinical Pathology, 2018, 71, 680-686.	1.0	35
173	Enhanced glutamine uptake influences composition of immune cell infiltrates in breast cancer. British Journal of Cancer, 2020, 122, 94-101.	2.9	35
174	Immunohistochemical analysis of IDH2 R172 hotspot mutations in breast papillary neoplasms: applications in the diagnosis of tall cell carcinoma with reverse polarity. Modern Pathology, 2020, 33, 1056-1064.	2.9	35
175	Low expression of G protein-coupled oestrogen receptor 1 (GPER) is associated with adverse survival of breast cancer patients. Oncotarget, 2018, 9, 25946-25956.	0.8	34
176	Combined HER3-EGFR score in triple-negative breast cancer provides prognostic and predictive significance superior to individual biomarkers. Scientific Reports, 2020, 10, 3009.	1.6	34
177	Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radioâ€resistance in breast cancer. Molecular Oncology, 2016, 10, 213-223.	2.1	33
178	The nucleolar-related protein Dyskerin pseudouridine synthase 1 (DKC1) predicts poor prognosis in breast cancer. British Journal of Cancer, 2020, 123, 1543-1552.	2.9	33
179	PIK3CÎ´ expression by fibroblasts promotes triple-negative breast cancer progression. Journal of Clinical Investigation, 2020, 130, 3188-3204.	3.9	33
180	Expression of the transcription factor CTCF in invasive breast cancer: a candidate gene located at 16q22.1. British Journal of Cancer, 2004, 91, 1591-1596.	2.9	32

#	Article	IF	Citations
181	The mammographic correlations of a new immunohistochemical classification of invasive breast cancer. Clinical Radiology, 2008, 63, 1228-1235.	0.5	32
182	Pitfalls in outcome prediction of breast cancer: TableÂ1. Journal of Clinical Pathology, 2013, 66, 458-464.	1.0	32
183	Characteristics of basal cytokeratin expression in breast cancer. Breast Cancer Research and Treatment, 2013, 139, 23-37.	1.1	32
184	Prolyl-4-hydroxylase Î‘ subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS). British Journal of Cancer, 2018, 119, 1518-1526.	2.9	32
185	Glutamate dehydrogenase (GLUD1) expression in breast cancer. Breast Cancer Research and Treatment, 2019, 174, 79-91.	1.1	32
186	Impact of Basal-Like Breast Carcinoma Determination for a More Specific Therapy. Pathobiology, 2008, 75, 95-103.	1.9	31
187	Infiltrating epitheliosis of the breast: characterization of histological features, immunophenotype and genomic profile. Histopathology, 2016, 68, 1030-1039.	1.6	31
188	Clinicopathological and prognostic significance of RECQL5 helicase expression in breast cancers. Carcinogenesis, 2016, 37, 63-71.	1.3	31
189	Inhibition of HER2 Increases JAGGED1-dependent Breast Cancer Stem Cells: Role for Membrane JAGGED1. Clinical Cancer Research, 2018, 24, 4566-4578.	3.2	31
190	Prognostic significance of cathepsin V (CTSV/CTSL2) in breast ductal carcinoma in situ. Journal of Clinical Pathology, 2020, 73, 76-82.	1.0	31
191	Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets. Breast Cancer Research, 2020, 22, 85.	2.2	31
192	HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer. Breast Cancer Research and Treatment, 2014, 145, 33-44.	1.1	30
193	Bimodality of intratumor Ki67 expression is an independent prognostic factor of overall survival in patients with invasive breast carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 493-502.	1.4	30
194	Prognostic stratification of oestrogen receptorâ€positive <scp>HER</scp>2â€negative lymph nodeâ€negative class of breast cancer. Histopathology, 2017, 70, 622-631.	1.6	30
195	Combining clustering and classification ensembles: A novel pipeline to identify breast cancer profiles. Artificial Intelligence in Medicine, 2019, 97, 27-37.	3.8	30
196	SUMOylation proteins in breast cancer. Breast Cancer Research and Treatment, 2014, 144, 519-530.	1.1	29
197	The prognostic significance of STAT3 in invasive breast cancer: analysis of protein and mRNA expressions in large cohorts. Breast Cancer Research and Treatment, 2016, 156, 9-20.	1.1	29
198	The role of PIP5K1Î±/pAKT and targeted inhibition of growth of subtypes of breast cancer using PIP5K1Î± inhibitor. Oncogene, 2019, 38, 375-389.	2.6	29

#	Article	IF	Citations
199	Histological grade of invasive carcinoma of the breast assessed on needle core biopsy - modifications to mitotic count assessment to improve agreement with surgical specimens. Histopathology, 2011, 59, 543-548.	1.6	28
200	TOMM34 expression in early invasive breast cancer: a biomarker associated with poor outcome. Breast Cancer Research and Treatment, 2012, 136, 419-427.	1.1	28
201	Imaging overview of metaplastic carcinomas of the breast: a large study of 71 cases. British Journal of Radiology, 2016, 89, 20140644.	1.0	28
202	The combined expression of solute carriers is associated with a poor prognosis in highly proliferative ER+ breast cancer. Breast Cancer Research and Treatment, 2019, 175, 27-38.	1.1	28
203	Molecular Complexity of Lymphovascular Invasion: The Role of Cell Migration in Breast Cancer as a Prototype. Pathobiology, 2020, 87, 218-231.	1.9	28
204	The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution. British Journal of Cancer, 2019, 120, 1075-1082.	2.9	27
205	Basal phenotype: a powerful prognostic factor in small screen-detected invasive breast cancer with long-term follow-up. Journal of Medical Screening, 2007, 14, 210-214.	1.1	26
206	Macroscopic handling and reporting of breast cancer specimens preâ€•and postâ€neoadjuvant chemotherapy treatment: review of pathological issues and suggested approaches. Histopathology, 2015, 67, 279-293.	1.6	26
207	Prognostic and biological significance of peroxisome proliferator-activated receptor-gamma in luminal breast cancer. Breast Cancer Research and Treatment, 2015, 150, 511-522.	1.1	26
208	Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma In Situ Induces Synthetic Lethality and Chemoprevention. Cancer Research, 2018, 78, 6818-6827.	0.4	26
209	ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers. Gynecologic Oncology, 2019, 153, 416-424.	0.6	26
210	The prognostic significance of immune microenvironment in breast ductal carcinoma in situ. British Journal of Cancer, 2020, 122, 1496-1506.	2.9	26
211	The prognostic significance of interferon-stimulated gene 15 (ISG15) in invasive breast cancer. Breast Cancer Research and Treatment, 2021, 185, 293-305.	1.1	26
212	Spindle cell lesions of the breast: a diagnostic approach. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 127-145.	1.4	26
213	Fatty acid binding protein 7 expression and its sub-cellular localization in breast cancer. Breast Cancer Research and Treatment, 2012, 134, 519-529.	1.1	25
214	Further evidence that <scp>E</scp>â€cadherin is not a tumour suppressor gene in invasive ductal carcinoma of the breast: an immunohistochemical study. Histopathology, 2013, 62, 695-701.	1.6	25
215	Papillary carcinoma of the breast: diagnostic agreement and management implications. Histopathology, 2016, 69, 862-870.	1.6	25
216	Invasion in breast lesions: the role of the epithelialâ€“stroma barrier. Histopathology, 2018, 72, 1075-1083.	1.6	25

#	Article	IF	Citations
217	A key genomic subtype associated with lymphovascular invasion in invasive breast cancer. British Journal of Cancer, 2019, 120, 1129-1136.	2.9	25
218	Connexin 43 is an independent predictor of patient outcome in breast cancer patients. Breast Cancer Research and Treatment, 2019, 174, 93-102.	1.1	25
219	The prognostic significance of ALDH1A1 expression in early invasive breast cancer. Histopathology, 2020, 77, 437-448.	1.6	25
220	Pleomorphic adenomas and mucoepidermoid carcinomas of the breast are underpinned by fusion genes. Npj Breast Cancer, 2020, 6, 20.	2.3	25
221	Overexpression of Specific CD44 Isoforms Is Associated with Aggressive Cell Features in Acquired Endocrine Resistance. Frontiers in Oncology, 2016, 6, 145.	1.3	24
222	Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer. Breast Cancer Research and Treatment, 2016, 157, 65-75.	1.1	24
223	Impact of breast cancer grade discordance on prediction of outcome. Histopathology, 2018, 73, 904-915.	1.6	24
224	Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer. International Journal of Molecular Sciences, 2020, 21, 1407.	1.8	24
225	Adenomyoepithelioma of the breast: a proposal for classification. Histopathology, 2021, 79, 465-479.	1.6	24
226	Current trials to reduce surgical intervention in ductal carcinoma in situ of the breast: Critical review. Breast, 2017, 35, 151-156.	0.9	24
227	Topo2Î± protein expression predicts response to anthracycline combination neo-adjuvant chemotherapy in locally advanced primary breast cancer. British Journal of Cancer, 2010, 103, 1794-1800.	2.9	23
228	The impact of using defined criteria for adequacy of fine needle aspiration cytology of the thyroid in routine practice. Diagnostic Cytopathology, 2011, 39, 81-86.	0.5	23
229	BQ323636.1, a Novel Splice Variant toNCOR2, as a Predictor for Tamoxifen-Resistant Breast Cancer. Clinical Cancer Research, 2018, 24, 3681-3691.	3.2	23
230	Thioredoxin-interacting protein is an independent risk stratifier for breast ductal carcinoma in situ. Modern Pathology, 2018, 31, 1807-1815.	2.9	23
231	Collagen (XI) alpha-1 chain is an independent prognostic factor in breast ductal carcinoma in situ. Modern Pathology, 2019, 32, 1460-1472.	2.9	23
232	High-resolution analysis of 16q22.1 in breast carcinoma using DNA amplifiable probes (multiplex) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 1 Cancer, 2005, 114, 720-729.	2.3	22
233	EpCAM expression is an indicator of recurrence in basal-like breast cancer. Breast Cancer Research and Treatment, 2012, 133, 575-582.	1.1	22
234	A review of the biological and clinical characteristics of luminalâ€like oestrogen receptorâ€positive breast cancer. Histopathology, 2012, 60, 854-863.	1.6	22

#	Article	IF	Citations
235	Clinicopathological and prognostic significance of mitogen-activated protein kinases (MAPK) in breast cancers. Breast Cancer Research and Treatment, 2016, 159, 457-467.	1.1	22
236	Phenotypic characterisation of breast cancer: the role of CDC42. Breast Cancer Research and Treatment, 2017, 164, 317-325.	1.1	22
237	Diagnostic concordance of breast pathologists: lessons from the National Health Service Breast Screening Programme Pathology External Quality Assurance Scheme. Histopathology, 2017, 70, 632-642.	1.6	22
238	PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancers. Cancer Letters, 2020, 469, 124-133.	3.2	22
239	Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer. Breast Cancer Research and Treatment, 2020, 181, 541-551.	1.1	22
240	A novel prognostic two-gene signature for triple negative breast cancer. Modern Pathology, 2020, 33, 2208-2220.	2.9	22
241	Centrosome amplification: a quantifiable cancer cell trait with prognostic value in solid malignancies. Cancer and Metastasis Reviews, 2021, 40, 319-339.	2.7	22
242	Screen-detected breast lesions with malignant needle core biopsy diagnoses and no malignancy identified in subsequent surgical excision specimens (potential false-positive diagnosis). European Journal of Cancer, 2009, 45, 1162-1167.	1.3	21
243	Overexpression of a novel cell cycle regulator ecdysoneless in breast cancer: a marker of poor prognosis in HER2/neu-overexpressing breast cancer patients. Breast Cancer Research and Treatment, 2012, 134, 171-180.	1.1	21
244	Markers of progression in early-stage invasive breast cancer: a predictive immunohistochemical panel algorithm for distant recurrence risk stratification. Breast Cancer Research and Treatment, 2015, 151, 325-333.	1.1	21
245	Assessment of HMGA2 and PLAG1 rearrangements in breast adenomyoepitheliomas. Npj Breast Cancer, 2019, 5, 6.	2.3	21
246	Atypical ductal hyperplasia is a multipotent precursor of breast carcinoma. Journal of Pathology, 2019, 248, 326-338.	2.1	21
247	Amplified centrosomes and mitotic index display poor concordance between patient tumors and cultured cancer cells. Scientific Reports, 2017, 7, 43984.	1.6	20
248	Predicting Metastasis Risk in Pancreatic Neuroendocrine Tumors Using Deep Learning Image Analysis. Frontiers in Oncology, 2020, 10, 593211.	1.3	20
249	Low calpain-9 is associated with adverse disease-specific survival following endocrine therapy in breast cancer. BMC Cancer, 2014, 14, 995.	1.1	19
250	Impact of intratumoural heterogeneity on the assessment of Ki67 expression in breast cancer. Breast Cancer Research and Treatment, 2016, 158, 287-295.	1.1	19
251	Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy. Breast Cancer Research and Treatment, 2018, 169, 277-286.	1.1	19
252	Legumain is an independent predictor for invasive recurrence in breast ductal carcinoma in situ. Modern Pathology, 2019, 32, 639-649.	2.9	19

#	Article	IF	Citations
253	Immunohistochemical assessment ofHRASQ61R mutations in breast adenomyoepitheliomas. Histopathology, 2020, 76, 865-874.	1.6	19
254	Digital pathology for primary diagnosis of screenâ€detected breast lesionsÂâ€“Âexperimental data, validation and experience from four centres. Histopathology, 2020, 76, 968-975.	1.6	19
255	Histological clues to the diagnosis of metastasis to the breast from extramammary malignancies. Histopathology, 2020, 77, 303-313.	1.6	19
256	The genetic architecture of breast papillary lesions as a predictor of progression to carcinoma. Npj Breast Cancer, 2020, 6, 9.	2.3	19
257	DNA repair prognostic index modelling reveals an essential role for base excision repair in influencing clinical outcomes in ER negative and triple negative breast cancers. Oncotarget, 2015, 6, 21964-21978.	0.8	19
258	Automated quality assessment of large digitised histology cohorts by artificial intelligence. Scientific Reports, 2022, 12, 5002.	1.6	19
259	Lack of expression of the proteins GMPR2 and PPARÎ± are associated with the basal phenotype and patient outcome in breast cancer. Breast Cancer Research and Treatment, 2013, 137, 127-137.	1.1	18
260	The microRNA maturation regulator Drosha is an independent predictor of outcome in breast cancer patients. Breast Cancer Research and Treatment, 2013, 137, 139-153.	1.1	18
261	Construction of tissue microarrays from core needle biopsies â€“ a systematic literature review. Histopathology, 2016, 68, 323-332.	1.6	18
262	The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer. Breast Cancer Research and Treatment, 2020, 179, 79-90.	1.1	18
263	Prognostic significance of KN motif and ankyrin repeat domains 1 (KANK1) in invasive breast cancer. Breast Cancer Research and Treatment, 2020, 179, 349-357.	1.1	18
264	Feasibility of integrated highâ€wavenumber Raman imaging and fingerprint Raman spectroscopy for fast margin assessment in breast cancer surgery. Journal of Raman Spectroscopy, 2020, 51, 1986-1995.	1.2	18
265	Assessment of mitotic activity in breast cancer: revisited in the digital pathology era. Journal of Clinical Pathology, 2022, 75, 365-372.	1.0	18
266	ERK1/2 is related to oestrogen receptor and predicts outcome in hormone-treated breast cancer. Breast Cancer Research and Treatment, 2014, 147, 25-37.	1.1	17
267	Clinicopathological and Functional Significance of RECQL1 Helicase in Sporadic Breast Cancers. Molecular Cancer Therapeutics, 2017, 16, 239-250.	1.9	17
268	Diagnostic concordance of reporting lymphovascular invasion in breast cancer. Journal of Clinical Pathology, 2018, 71, 802-805.	1.0	17
269	Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+â€‰breast cancer. Breast Cancer Research and Treatment, 2019, 173, 93-102.	1.1	17
270	Cytological assessment of conventional transbronchial fine needle aspiration of lymph nodes. Cytopathology, 2010, 21, 27-34.	0.4	16

#	Article	IF	Citations
271	Lowâ€“Estrogen Receptorâ€“Positive Breast Cancer: The Impact of Tissue Sampling, Choice of Antibody, and Molecular Subtyping. Journal of Clinical Oncology, 2012, 30, 2929-2930.	0.8	16
272	Clinical utility of reverse phase protein array for molecular classification of breast cancer. Breast Cancer Research and Treatment, 2016, 155, 25-35.	1.1	16
273	Rho-GTPase activating-protein 18: a biomarker associated with good prognosis in invasive breast cancer. British Journal of Cancer, 2017, 117, 1176-1184.	2.9	16
274	Wholeâ€exome sequencing and RNA sequencing analyses of acinic cell carcinomas of the breast. Histopathology, 2019, 75, 931-937.	1.6	16
275	The prognostic significance of lysosomal protective protein (cathepsin A) in breast ductal carcinoma inÂsitu. Histopathology, 2019, 74, 1025-1035.	1.6	16
276	Artificial intelligence for advance requesting of immunohistochemistry in diagnostically uncertain prostate biopsies. Modern Pathology, 2021, 34, 1780-1794.	2.9	16
277	Standardization of the tumor-stroma ratio scoring method for breast cancer research. Breast Cancer Research and Treatment, 2022, 193, 545-553.	1.1	16
278	Cytoplasmic localization of alteration/deficiency in activation 3 (ADA3) predicts poor clinical outcome in breast cancer patients. Breast Cancer Research and Treatment, 2013, 137, 721-731.	1.1	15
279	Cell Proliferation (KI-67) Expression Is Associated with Poorer Prognosis in Nigerian Compared to British Breast Cancer Women. ISRN Oncology, 2013, 2013, 1-8.	2.1	15
280	Characterisation of HER heterodimers in breast cancer using in situ proximity ligation assay. Breast Cancer Research and Treatment, 2014, 144, 273-285.	1.1	15
281	Pleomorphic adenomaâ€like tumour of the breast. Histopathology, 2016, 68, 405-410.	1.6	15
282	Current issues with luminal subtype classification in terms of prediction of benefit from endocrine therapy in early breast cancer. Histopathology, 2018, 73, 545-558.	1.6	15
283	Visual histological assessment of morphological features reflects the underlying molecular profile in invasive breast cancer: a morphomolecular study. Histopathology, 2020, 77, 631-645.	1.6	15
284	Invasive Lobular Carcinoma Mimicking Papillary Carcinoma: A Report of Three Cases. Pathobiology, 2016, 83, 221-227.	1.9	14
285	Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers. British Journal of Cancer, 2017, 117, 826-834.	2.9	14
286	Prognostic significance of nucleolar assessment in invasive breast cancer. Histopathology, 2020, 76, 671-684.	1.6	14
287	The expression of ERÎ±, ERÎ² and PR in lobular carcinoma in situ of the breast determined using laser microdissection and realâ€time PCR. Histopathology, 2009, 54, 419-427.	1.6	13
288	Updated guideline recommendations for HER2 testing. Nature Reviews Clinical Oncology, 2014, 11, 8-9.	12.5	13

#	Article	IF	Citations
289	Breast conservation in ductal carcinoma in situ (DCIS): what defines optimal margins?. Histopathology, 2017, 70, 681-692.	1.6	13
290	Saccharomyces cerevisiae-like 1 (SEC14L1) is a prognostic factor in breast cancer associated with lymphovascular invasion. Modern Pathology, 2018, 31, 1675-1682.	2.9	13
291	Outcome of radial scar/complex sclerosing lesion associated with epithelial proliferations with atypia diagnosed on breast core biopsy: results from a multicentric UK-based study. Journal of Clinical Pathology, 2019, 72, 800-804.	1.0	13
292	Clinicopathological significance of lipocalin 2 nuclear expression in invasive breast cancer. Breast Cancer Research and Treatment, 2020, 179, 557-564.	1.1	13
293	Metaplastic carcinomas of the breast without evidence of epithelial differentiation: a diagnostic approach for management. Histopathology, 2021, 78, 759-771.	1.6	13
294	Artificial intelligence grading of breast cancer: a promising method to refine prognostic classification for management precision. Histopathology, 2021, 79, 187-199.	1.6	13
295	Predicting the Economic Impact of the COVID-19 Pandemic in the United Kingdom Using Time-Series Mining. Economies, 2021, 9, 137.	1.2	13
296	FKBPL: a marker of good prognosis in breast cancer. Oncotarget, 2015, 6, 12209-12223.	0.8	13
297	Association of L-type amino acid transporter 1 (LAT1) with the immune system and prognosis in invasive breast cancer. Scientific Reports, 2022, 12, 2742.	1.6	13
298	Influence of E-cadherin Expression on the Mammographic Appearance of Invasive Nonlobular Breast Carcinoma Detected at Screening. Radiology, 2009, 253, 51-55.	3.6	12
299	Adverse prognostic and predictive significance of low DNA-dependent protein kinase catalytic subunit (DNA-PKcs) expression in early-stage breast cancers. Breast Cancer Research and Treatment, 2014, 146, 309-320.	1.1	12
300	Further evidence to support bimodality of oestrogen receptor expression in breast cancer. Histopathology, 2017, 70, 456-465.	1.6	12
301	Clinical and biological roles of Kelch-like family member 7 in breast cancer: a marker of poor prognosis. Breast Cancer Research and Treatment, 2018, 170, 525-533.	1.1	12
302	High nuclear MSK1 is associated with longer survival in breast cancer patients. Journal of Cancer Research and Clinical Oncology, 2018, 144, 509-517.	1.2	12
303	The effect of human placental chorionic villi derived mesenchymal stem cell on triple-negative breast cancer hallmarks. PLoS ONE, 2018, 13, e0207593.	1.1	12
304	ATM Regulated PTEN Degradation Is XIAP E3 Ubiquitin Ligase Mediated in p85Î± Deficient Cancer Cells and Influence Platinum Sensitivity. Cells, 2019, 8, 1271.	1.8	12
305	The intra-tumoural stroma in patients with breast cancer increases with age. Breast Cancer Research and Treatment, 2020, 179, 37-45.	1.1	12
306	The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer. Breast Cancer Research and Treatment, 2020, 181, 1-12.	1.1	12

#	Article	IF	Citations
307	Molecular disruption of DNA polymerase Î² for platinum sensitisation and synthetic lethality in epithelial ovarian cancers. Oncogene, 2021, 40, 2496-2508.	2.6	12
308	FEN1 Blockade for Platinum Chemo-Sensitization and Synthetic Lethality in Epithelial Ovarian Cancers. Cancers, 2021, 13, 1866.	1.7	12
309	Specific cell differentiation in breast cancer: a basis for histological classification. Journal of Clinical Pathology, 2022, 75, 76-84.	1.0	12
310	Visual assessment of mitotic figures in breast cancer: a comparative study between light microscopy and whole slide images. Histopathology, 2021, 79, 913-925.	1.6	12
311	The ITIM-Containing Receptor: Leukocyte-Associated Immunoglobulin-Like Receptor-1 (LAIR-1) Modulates Immune Response and Confers Poor Prognosis in Invasive Breast Carcinoma. Cancers, 2021, 13, 80.	1.7	12
312	Hypoxia Drives Centrosome Amplification in Cancer Cells via HIF1Î±-dependent Induction of Polo-Like Kinase 4. Molecular Cancer Research, 2022, 20, 596-606.	1.5	12
313	Letter to the Editor. Modern Pathology, 2008, 21, 1060-1061.	2.9	11
314	Evaluation of touch preparation cytology during frozen-section diagnoses of pulmonary lesions. Journal of Clinical Pathology, 2010, 63, 675-677.	1.0	11
315	Geometric characteristics of collagen have independent prognostic significance in breast ductal carcinoma in situ: an image analysis study. Modern Pathology, 2019, 32, 1473-1485.	2.9	11
316	Dopamine and cAMP-regulated phosphoprotein 32â€‰kDa (DARPP-32) and survival in breast cancer: a retrospective analysis of protein and mRNA expression. Scientific Reports, 2019, 9, 16987.	1.6	11
317	Nucleolar protein 10 (NOP10) predicts poor prognosis in invasive breast cancer. Breast Cancer Research and Treatment, 2021, 185, 615-627.	1.1	11
318	Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patientsÂundergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio â‰¥2.0, HER2) Tj ETQq0 0 0 rgBT /Overloc		
319	RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer. Breast Cancer Research, 2021, 23, 42.	2.2	11
320	PP1, PKA and DARPPâ€32 in breast cancer: A retrospective assessment of protein and mRNA expression. Journal of Cellular and Molecular Medicine, 2021, 25, 5015-5024.	1.6	11
321	Assessment of proliferation in breast cancer: cell cycle or mitosis? An observational study. Histopathology, 2021, 79, 1087-1098.	1.6	11
322	Ubiquitin-conjugating enzyme 2C (UBE2C) is a poor prognostic biomarker in invasive breast cancer. Breast Cancer Research and Treatment, 2022, 192, 529-539.	1.1	11
323	Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer. Npj Breast Cancer, 2022, 8, 57.	2.3	11
324	The prognostic significance of early stage lymph node positivity in operable invasive breast carcinoma: number or stage. Journal of Clinical Pathology, 2012, 65, 624-630.	1.0	10

#	Article	IF	Citations
325	The low nuclear grade breast neoplasia family. Diagnostic Histopathology, 2012, 18, 124-132.	0.2	10
326	PIASÎ³ expression in relation to clinicopathological, tumour factors and survival in indigenous black breast cancer women. Journal of Clinical Pathology, 2014, 67, 301-306.	1.0	10
327	Prognostic and biological significance of proliferation and HER2 expression in the luminal class of breast cancer. Breast Cancer Research and Treatment, 2014, 145, 317-330.	1.1	10
328	The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer: the impact of oestrogen receptor and HER2 pathways. Breast Cancer Research and Treatment, 2015, 150, 91-103.	1.1	10
329	Stratification of resectable lung adenocarcinoma by molecular and pathological risk estimators. European Journal of Cancer, 2015, 51, 1897-1903.	1.3	10
330	ADA3 regulates normal and tumor mammary epithelial cell proliferation through c-MYC. Breast Cancer Research, 2016, 18, 113.	2.2	10
331	Checkpoint Kinase 1 Expression Predicts Poor Prognosis in Nigerian Breast Cancer Patients. Molecular Diagnosis and Therapy, 2018, 22, 79-90.	1.6	10
332	Clinicopathological and prognostic significance of Ras association and pleckstrin homology domains 1 (RAPH1) in breast cancer. Breast Cancer Research and Treatment, 2018, 172, 61-68.	1.1	10
333	Retinoid X receptor gamma (RXRG) is an independent prognostic biomarker in ER-positive invasive breast cancer. British Journal of Cancer, 2019, 121, 776-785.	2.9	10
334	PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer. BMC Cancer, 2020, 20, 425.	1.1	10
335	Ligase 1 is a predictor of platinum resistance and its blockade is synthetically lethal in XRCC1 deficient epithelial ovarian cancers. Theranostics, 2021, 11, 8350-8361.	4.6	10
336	XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592097420.	1.4	10
337	The relationship of CDK18 expression in breast cancer to clinicopathological parameters and therapeutic response. Oncotarget, 2018, 9, 29508-29524.	0.8	10
338	Molecular profiling of breast cancer in Nigerian women identifies an altered p53 pathway as a major mechanism underlying its poor prognosis compared with British counterpart. Malaysian Journal of Pathology, 2014, 36, 3-17.	0.1	10
339	Gigantic recurrent abdominal desmoid tumour: a case report. Hernia: the Journal of Hernias and Abdominal Wall Surgery, 2007, 11, 193-197.	0.9	9
340	Infiltrative epitheliosis of the breast. Journal of Clinical Pathology, 2012, 65, 766-768.	1.0	9
341	Chemokine (Câ€€ motif) receptor 7 (CCR7) associates with the tumour immune microenvironment but not progression in invasive breast carcinoma. Journal of Pathology: Clinical Research, 2017, 3, 105-114.	1.3	9
342	Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes. British Journal of Cancer, 2018, 118, 1142-1151.	2.9	9

#	Article	IF	Citations
343	Machine learning-based prediction of breast cancer growth rate in vivo. British Journal of Cancer, 2019, 121, 497-504.	2.9	9
344	ERCC1 Is a Predictor of Anthracycline Resistance and Taxane Sensitivity in Early Stage or Locally Advanced Breast Cancers. Cancers, 2019, 11, 1149.	1.7	9
345	Clinicopathological significance of ataxia telangiectasia-mutated (ATM) kinase and ataxia telangiectasia-mutated and Rad3-related (ATR) kinase in MYC overexpressed breast cancers. Breast Cancer Research and Treatment, 2019, 175, 105-115.	1.1	9
346	The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes. Breast Cancer Research and Treatment, 2020, 182, 581-589.	1.1	9
347	Defining the area of mitoses counting in invasive breast cancer using whole slide image. Modern Pathology, 2022, 35, 739-748.	2.9	9
348	The characteristics and clinical significance of atypical mitosis in breast cancer. Modern Pathology, 2022, 35, 1341-1348.	2.9	9
349	The value of examination of multiple levels of mammary needle core biopsy specimens taken for investigation of lesions other than calcification. Journal of Clinical Pathology, 2012, 65, 1097-1099.	1.0	8
350	Human epidermal growth factor receptor 2 testing in invasive breast cancer: should histological grade, type and oestrogen receptor status influence the decision to repeat testing?. Histopathology, 2016, 69, 20-24.	1.6	8
351	Androgen dependent mechanisms of pro-angiogenic networks in placental and tumor development. Placenta, 2017, 56, 79-85.	0.7	8
352	Retrospective assessment of cyclinâ€dependent kinase 5 mRNA and protein expression and its association with patient survival in breast cancer. Journal of Cellular and Molecular Medicine, 2020, 24, 6263-6271.	1.6	8
353	Werner Syndrome Protein Expression in Breast Cancer. Clinical Breast Cancer, 2021, 21, 57-73.e7.	1.1	8
354	Combined total internal reflection AF spectral-imaging and Raman spectroscopy for fast assessment of surgical margins during breast cancer surgery. Biomedical Optics Express, 2021, 12, 940.	1.5	8
355	The Biological and Clinical Significance of Glutaminase in Luminal Breast Cancer. Cancers, 2021, 13, 3963.	1.7	8
356	RAD50 deficiency is a predictor of platinum sensitivity in sporadic epithelial ovarian cancers. Molecular Biomedicine, 2020, 1, 19.	1.7	8
357	Nuclear morphology in breast lesions: refining its assessment to improve diagnostic concordance. Histopathology, 2022, 80, 515-528.	1.6	8
358	Untangling the clinicopathological significance of MRE11-RAD50-NBS1 complex in sporadic breast cancers. Npj Breast Cancer, 2021, 7, 143.	2.3	8
359	Potential quality pitfalls of digitalized whole slide image of breast pathology in routine practice. Modern Pathology, 2022, 35, 903-910.	2.9	8
360	Screen-detected malignant breast lesions diagnosed following benign (B2) or normal (B1) needle core biopsy diagnoses. European Journal of Cancer, 2010, 46, 1835-1840.	1.3	7

#	Article	IF	Citations
361	Morphogenesis of the papillary lesions of the breast: phenotypic observation. Journal of Clinical Pathology, 2016, 69, 64-69.	1.0	7
362	Panoptic Overview of Triple-Negative Breast Cancer in Nigeria: Current Challenges and Promising Global Initiatives. Journal of Global Oncology, 2018, 4, 1-20.	0.5	7
363	Surgical management of ductal carcinoma in situ of the breast: A large retrospective study from a single institution. Breast Journal, 2019, 25, 1143-1153.	0.4	7
364	Utility of ankyrin 3 as a prognostic marker in androgen-receptor-positive breast cancer. Breast Cancer Research and Treatment, 2019, 176, 63-73.	1.1	7
365	Breast Tumours Resembling the Tall Cell Variant of Thyroid Papillary Carcinoma: Are They Part of the Papillary Carcinoma Spectrum or a Distinct Entity?. Pathobiology, 2019, 86, 83-91.	1.9	7
366	Integrated Analysis of Key Differentially Expressed Genes Identifies DBN1 as a Predictive Marker of Response to Endocrine Therapy in Luminal Breast Cancer. Cancers, 2020, 12, 1549.	1.7	7
367	Atypia in breast pathology: what pathologists need to know. Pathology, 2021, , .	0.3	7
368	Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results. Clinical Cancer Research, 2022, 28, 1323-1334.	3.2	7
369	Digital Technology in Diagnostic Breast Pathology and Immunohistochemistry. Pathobiology, 2022, 89, 334-342.	1.9	7
370	Assessment of Predictive Biomarkers in Breast Cancer: Challenges and Updates. Pathobiology, 2022, 89, 263-277.	1.9	7
371	Breast Neoplasms with Dermal Analogue Differentiation (Mammary Cylindroma): Report of 3 Cases and a Proposal for a New Terminology. Pathobiology, 2015, 82, 172-178.	1.9	6
372	Eighth Edition Cancer Staging Manual of Breast Cancer by the American Joint Committee on Cancer: are the new changes to improve staging or a treatment decision tool?. Journal of Clinical Pathology, 2018, 71, 1028-1029.	1.0	6
373	The Mammalian Ecdysoneless Protein Interacts with RNA Helicase DDX39A To Regulate Nuclear mRNA Export. Molecular and Cellular Biology, 2021, 41, e0010321.	1.1	6
374	Diagnostic concordance of phyllodes tumour of the breast. Histopathology, 2021, 79, 607-618.	1.6	6
375	Oestrogen-regulated protein SLC39A6: a biomarker of good prognosis in luminal breast cancer. Breast Cancer Research and Treatment, 2021, 189, 621-630.	1.1	6
376	Are triple negative tumours and basal-like breast cancer synonymous?. Breast Cancer Research, 2007, 9, R80.	2.2	6
377	Ecdysoneless Protein Regulates Viral and Cellular mRNA Splicing to Promote Cervical Oncogenesis. Molecular Cancer Research, 2022, 20, 305-318.	1.5	6
378	Prognostic significance of receptor expression discordance between primary and recurrent breast cancers: a meta-analysis. Breast Cancer Research and Treatment, 2022, 191, 1-14.	1.1	6

#	Article	IF	Citations
379	Efficacy of an incident-reporting system in cellular pathology: a practical experience. Journal of Clinical Pathology, 2012, 65, 643-648.	1.0	5
380	Clinicopathological and molecular characteristics of Ku 70/80 expression in Nigerian breast cancer and its potential therapeutic implications. Pathology Research and Practice, 2017, 213, 27-33.	1.0	5
381	Clinicopathological and Functional Evaluation Reveal NBS1 as a Predictor of Platinum Resistance in Epithelial Ovarian Cancers. Biomedicines, 2021, 9, 56.	1.4	5
382	Correlations of morphological features and surgical management with clinical outcome in a multicentre study of 241 phyllodes tumours of the breast. Histopathology, 2021, 78, 871-881.	1.6	5
383	SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer. Breast Cancer Research and Treatment, 2021, 189, 317-331.	1.1	5
384	Head to head: Do neuroendocrine tumours in the breast truly exist?. Histopathology, 2022, , .	1.6	5
385	Integrating Breast Cancer Genetics into Clinical Practice. Women's Health, 2012, 8, 99-112.	0.7	4
386	The clinical significance of oestrogen receptor expression in breast ductal carcinoma in situ. British Journal of Cancer, 2020, 123, 1513-1520.	2.9	4
387	A Quantitative Centrosomal Amplification Score Predicts Local Recurrence of Ductal Carcinoma In Situ. Clinical Cancer Research, 2020, 26, 2898-2907.	3.2	4
388	Age-Related Biology of Early-Stage Operable Breast Cancer and Its Impact on Clinical Outcome. Cancers, 2021, 13, 1417.	1.7	4
389	The prognostic significance of Flap Endonuclease 1 (FEN1) in breast ductal carcinoma in situ. Breast Cancer Research and Treatment, 2021, 188, 53-63.	1.1	4
390	Flower lose, a cell fitness marker, predicts COVIDâ€19 prognosis. EMBO Molecular Medicine, 2021, 13, e13714.	3.3	4
391	Intra-operative assessment of sentinel lymph nodes for breast cancer surgery: An update. Surgical Oncology, 2022, 40, 101678.	0.8	4
392	Reâ€audit of revised method for assessing the mitotic component of histological grade in needle core biopsies of invasive carcinoma of the breast. Histopathology, 2012, 60, 1166-1167.	1.6	3
393	Co-expression of nuclear P38 and hormone receptors is prognostic of good long-term clinical outcome in primary breast cancer and is linked to upregulation of DNA repair. BMC Cancer, 2018, 18, 1027.	1.1	3
394	SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment. British Journal of Cancer, 2019, 120, 728-745.	2.9	3
395	Will MRI screening deliver the expected survival advantage in BRCA 1 carriers?. Clinical Radiology, 2009, 64, 1045-1047.	0.5	2
396	Breast pathology today: morphology and molecules. Journal of Clinical Pathology, 2013, 66, 457-457.	1.0	1

#	Article	IF	Citations
397	Molecular-Based Diagnostic, Prognostic and Predictive Tests in Breast Cancer. Molecular Pathology Library, 2015, , 177-195.	0.1	1
398	Molecular Pathology of Breast Cancer Metastasis. Molecular Pathology Library, 2015, , 271-289.	0.1	1
399	Molecular Pathology of Precancerous Lesions of the Breast. Molecular Pathology Library, 2015, , 51-62.	0.1	1
400	Reply to Rosen. Modern Pathology, 2017, 30, 1505-1506.	2.9	1
401	The frequency and clinical significance of DNA polymerase beta (POLÎ²) expression in breast ductal carcinoma in situ (DCIS). Breast Cancer Research and Treatment, 2021, 190, 39-51.	1.1	1
402	Grading of Invasive Carcinoma. , 2017, , 87-95.		1
403	Invasive Ductal Carcinoma of No Special Type and Histologic Grade. , 2012, , 429-445.		1
404	A multi-institutional study of racial differences in androgen receptor status among triple-negative breast cancers.. Journal of Clinical Oncology, 2016, 34, 1089-1089.	0.8	1
405	Papillary Carcinomas. , 2017, , 137-152.		1
406	Prognostic significance of heat shock protein 90AA1 (HSP90Î±) in invasive breast cancer. Journal of Clinical Pathology, 2022, 75, 263-269.	1.0	1
407	Lessons from a breast cell annotation competition series for school pupils. Scientific Reports, 2022, 12, 7792.	1.6	1
408	Aurora Kinase A Is an Independent Predictor of Invasive Recurrence in Breast Ductal Carcinoma in situ. Pathobiology, 2022, 89, 382-392.	1.9	1
409	Authors' reply: combining two antibodies to define <scp>E</scp>â€cadherin loss of expression in nonâ€lobular breast carcinomas: when less is more. Histopathology, 2013, 63, 440-443.	1.6	0
410	Brief Fixation and Hormone Receptor Expression in Breast Cancer. American Journal of Surgical Pathology, 2015, 39, 425.	2.1	0
411	Molecular Classification of Breast Cancer. Molecular Pathology Library, 2015, , 137-155.	0.1	0
412	Novel Immunohistochemical Based Biomarkers in Breast Cancer. , 2016, , 99-119.		0
413	Current topics in breast pathology: expert perspectives. Pathology, 2017, 49, 109-110.	0.3	0
414	Histological risk factors, prognostic indicators and staging. , 2013, , 236-249.		0

#	Article	IF	Citations
415	Abstract B120: Ada3, a component of ATAC complex is involved in regulation of the Genomic stability, DNA repair process and breast cancer. , 2013, , .		0
416	Pathology and biology of breast cancer. , 2014, , 20-43.		0
417	Predicting chemotherapy response in invasive breast cancer.. Journal of Clinical Oncology, 2014, 32, 1084-1084.	0.8	0
418	Raman spectral histopathology of breast cancer recession margins. , 2016, , .		0
419	Potential of a novel technique for constructing tissue microarrays from core needle biopsy as seen in older women with primary breast cancer.. Journal of Clinical Oncology, 2016, 34, e23283-e23283.	0.8	0
420	Multi-institutional study of triple negative breast cancer stratification by a metric that quantifies cell cycling kinetics.. Journal of Clinical Oncology, 2016, 34, 1091-1091.	0.8	0
421	Identifying likely metastatic sites for triple negative breast cancers using immunohistochemical biomarkers.. Journal of Clinical Oncology, 2016, 34, 1092-1092.	0.8	0
422	A combined HER3-EGFR score in triple-negative breast cancer: racial differences.. Journal of Clinical Oncology, 2016, 34, e12560-e12560.	0.8	0
423	Metaplastic Breast Carcinomas. , 2017, , 153-166.		0
424	Intra-operative Assessment of Excision margins During Breast Conserving Surgery by Integrated Raman Microscopy and Auto-fluorescence Imaging. , 2018, , .		0
425	Tubular Carcinoma. Encyclopedia of Pathology, 2020, , 384-387.	0.0	0
426	Quantifying Lymphatic in Human Tissue Samples. Methods in Molecular Biology, 2022, 2441, 183-189.	0.4	0
427	Applications and implications of whole-slide imaging in breast pathology. Diagnostic Histopathology, 2022, 28, 149-155.	0.2	0
428	Upregulation of Cyclin B2 () in breast cancer contributes to the development of lymphovascular invasion.. American Journal of Cancer Research, 2022, 12, 469-489.	1.4	0